Acquisitions

M&A activity

20 stories

Bullish 6

Supernus–Indivior Merger Creates 11-Drug CNS Giant, $125M Synergy Target

Supernus Pharmaceuticals is acquiring Indivior in an all-stock deal, assembling a portfolio of 11 FDA-approved CNS treatments. The merger targets $125 million in annual cost synergies and expands the company's footprint in neurology, addiction, and psychiatry. Meanwhile, Q2 revenue jumped 32% to $219 million, but a surprise net loss of $58.1 million casts a shadow over short-term integration risks.

Verified by 4 sources

Source: The Motley Fool · Eric Volkman (us)

Neutral 9

AZN-BMS $400B Talks: What It Means for Drug Prices and Access

A potential $400 billion merger between AstraZeneca and Bristol Myers Squibb could reshape oncology competition, with implications for drug costs, patient access, and payer negotiations. The combined portfolio would dominate key cancer markets.

Verified by 2 sources
Bullish 6

Aurobindo’s $250M Lannett Buy Adds 4B Dose Capacity, FTC OKs

FTC approval paves the way for Aurobindo Pharma to acquire Lannett Company, adding a 4 billion dose manufacturing facility and complex non-opioid generics portfolio to its network, directly supporting US efforts to boost domestic drug production and address the opioid crisis.

Verified by 2 sources
Bullish 8

Samsung Biologics' $1.46B Peptide Acquisition Secures Global Drug Supply Chain

Samsung Biologics' tender offer for PolyPeptide brings peptide API manufacturing in-house, reinforcing supply chain resilience for hormone therapies, antibiotics, and emerging biotherapeutics. The deal expands capacity across the U.S., Europe, and India, potentially reducing the risk of shortages that have plagued certain peptide drugs.

Verified by 2 sources
Bullish 7

H.B. Fuller's £659M AMS Deal Powers 35% Premium into Medical Adhesives Market

H.B. Fuller's $870 million acquisition of Advanced Medical Solutions signals a major vote of confidence in advanced wound care and surgical sealants. For healthcare providers, this deal promises innovative products for chronic wounds and surgical closures, potentially improving patient outcomes and reducing costs.

Verified by 2 sources
Bullish 7

Wellgistics Health Targets CNS Market with $105M Neuritek Acquisition Bid

Wellgistics Health Inc. has signed a $105 million Letter of Intent to evaluate the acquisition of Neuritek Therapeutics, a biotech firm specializing in neurological and psychiatric treatments. The deal marks a significant strategic expansion for Wellgistics into the high-growth central nervous system (CNS) therapeutic sector.

Verified by 2 sources

Source: jamaicantimes.com · californiatelegraph.com

Bullish 8

Novartis Bolsters Oncology Pipeline with $3B Acquisition of SNV4818

Novartis AG has entered into a definitive agreement to acquire an experimental breast cancer drug candidate, SNV4818, from Delaware-based Synnovation Therapeutics for up to $3 billion. This strategic acquisition aims to strengthen Novartis's leadership in the oncology market as it continues its pivot toward high-value innovative medicines.

Verified by 3 sources

Source: Seeking Alpha · Bloomberg

Very Bullish 6

Aster DM Healthcare Secures Shareholder Approval for Landmark QCIL Merger

Aster DM Healthcare has cleared a critical regulatory hurdle as shareholders and creditors overwhelmingly approved its merger with Quality Care India Limited (QCIL). This consolidation, backed by Blackstone, is set to create one of India's largest private healthcare networks with a significantly expanded bed capacity and geographic footprint.

Verified by 2 sources

Source: thehindubusinessline.com · nepalnational.com

Bullish 6

Lifeward and Oramed Secure Shareholder Approval for Strategic Biomedical Merger

Lifeward Ltd shareholders have officially approved a strategic partnership with Oramed Pharmaceuticals, signaling a major pivot toward becoming a diversified biomedical company. The deal integrates Lifeward's robotic rehabilitation technology with Oramed's pharmaceutical expertise to create a multi-disciplinary healthcare entity.

Verified by 2 sources

Source: finanznachrichten.de · manilatimes.net

Neutral 7

Universal Health Services to Acquire Talkspace for $835 Million

Universal Health Services (UHS) has reached a definitive agreement to acquire virtual mental health provider Talkspace for $835 million. The deal merges one of the nation's largest inpatient behavioral health networks with a leading digital therapy platform, signaling a major shift toward hybrid care models.

Verified by 2 sources

Source: STAT News · Endpoints News

Bullish 7

Hims & Hers Acquires Eucalyptus for $1.6B in Global Telehealth Consolidation

US telehealth leader Hims & Hers has finalized a $1.6 billion acquisition of Australian digital health startup Eucalyptus, marking a major expansion into the Asia-Pacific market. The deal, driven by the explosive growth of GLP-1 weight-loss treatments, creates over 100 employee millionaires and solidifies Hims & Hers' position as a global powerhouse in direct-to-consumer healthcare.

Verified by 2 sources

About Healthcare Acquisitions coverage

According to our own tracking database, this category has accumulated 20 acquisitions stories since coverage began. This page aggregates the latest acquisitions stories within our healthcare coverage area. Every story is cross-referenced across multiple primary sources, scored for sentiment and operational impact, and timestamped so fresh developments surface first. We track m&a activity and surface the angles a domain expert would actually read.

Story selection follows our editorial methodology — impact scoring weights regulatory, financial, and operational developments distinctly. Sentiment is classified across five tiers via supervised classification trained on labeled industry corpora. See our glossary for term definitions and our trends index for longitudinal patterns across the healthcare beat.

Stories only surface on this page once the classifier scores them at a minimum 35 percent relevance to the category. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.

See something wrong on this page — a wrong stat, a broken source link, a miscategorized story? Report a data issue.

SignalWhat it tells you
Verified by N sourcesConfidence the story isn't a single-source rumor — N≥2 means the development is independently corroborated.
Impact score (1-10)Estimated regulatory, financial, or operational impact. 8+ indicates a story experienced operators should act on.
SentimentFive-tier classification (very bullish through very bearish) trained on labeled healthcare-specific corpora.
Time stampRecency. Fresh stories (under 1h) render with a highlighted timestamp; stale stories (≥24h) render dimmed.